• Home
  • NEW DAY MEDICINE
  • 9 (47) 2022
  • 69 — 9 (47) 2022 — Jumaeva M.F., FREQUENCY OF HEPATORENAL SYNDROME IN PATIENTS WITH LIVER CIRRHOSIS OF DIFFERENT ETIOLOGIES

69 — 9 (47) 2022 — Jumaeva M.F., FREQUENCY OF HEPATORENAL SYNDROME IN PATIENTS WITH LIVER CIRRHOSIS OF DIFFERENT ETIOLOGIES

FREQUENCY OF HEPATORENAL SYNDROME IN PATIENTS WITH LIVER CIRRHOSIS OF DIFFERENT ETIOLOGIES

Jumaeva M.F., Bukhara State Medical Institute

Resume

Hepatorenal syndrome is a progressive renal failure that develops against a background of severe liver disease with liver failure and portal hypertension syndrome. This pathology is relevant, because the life prognosis for it is extremely unfavorable. The average survival period for hepatorenal syndrome type I is 10-14 days, and for type II – 15-30 days, regardless of the class of the disease according to Childe-Pugh.

Key word: Hepatorenal syndrome, the frequency of occurrence of cirrhosis of the liver of various etiologies

First page

417

Last page

419

For citation: Jumaeva M.F., FREQUENCY OF HEPATORENAL SYNDROME IN PATIENTS WITH LIVER CIRRHOSIS OF DIFFERENT ETIOLOGIES //New Day in Medicine 9 (47)2022 417-419 https://l.clck.bar/70c4b

LIST OF REFERENCES:

  1. Acevedo JG, Cramp ME. Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol. 2017 Feb 28;9(6):293-299. DOI: https://doi.org/10.4254/wjh.v9.i6.293
  2. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019 Oct;71(4):811-822. DOI: https://doi.org/10.1016/j.jhep.2019.07.002
  3. Belcher, J.M. Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & MetaAnalysis / J.M. Belcher, S.G. Coca, C.R. Parikh. // PLoS One. – 2015. – Vol.21, N.8. – e0135625. https://doi.org/10.1371/journal.pone.0135625
  4. Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993 Jul;105(1):229-236.DOI: https://doi.org/10.1016/0016-5085(93)90031-7
  5. Gines P, Guevara M. Hepatorenal syndrome. Lancet. 2003 Nov 29;362(9398):1819-1827.DOI: https://doi.org/10.1016/S0140-6736(03)14903-3
  6. Jumaeva M.F.. Hepatocardiorenal syndrome. Asian journal of Pharmaceutical and biological research 2231-2218. Volume 11 Issue 1 JAN-APR 2022 https://doi.org/10.5281/zenodo.6473017 pages 82-97
  7. Facciorusso A. Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects. Ther Clin Risk Manag. 2019 Nov 27;15:1383-1391. DOI: https://doi.org/10.2147/TCRM.S205328
  8. Francesco S, Gerbes A, Ginès P, Wong F, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007 Sep;56(9):1310-1318.DOI: https://doi.org/10.1136/gut.2006.107789
  9. Lata J. Hepatorenal syndrome. World J Gastroenterol. 2012 Sep 28;18(36):4978-4984. DOI: https://doi.org/10.3748/wjg.v18.i36.4978
  10. Low G, Alexander GJM, Lomas DJ. Hepatorenal Syndrome: Aetiology, Diagnosis, and Treatment. Gastroenterol Res Pract. 2015;2015:207012.DOI: https://doi.org/10.1155/2015/207012

file

download